Increased Bone Marrow Iron Stores Is an Independent Risk Factor for Invasive Aspergillosis in Patients With High-Risk Hematologic Malignancies and Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Dimitrios P. Kontoyiannis, MD1
Georgios Chamilos, MD1
Russell E. Lewis, PharmD1
Sergio Giralt, MD2
Jorge Cortes, MD2
Issam I. Raad, MD1
John T. Manning, MD3
Xin Han, MD3

1 Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
2 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
3 Department of Leukemia, Pathology, and Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

BACKGROUND. Invasive aspergillosis (IA) is a leading cause of death in patients with leukemia and those who have undergone hematopoietic stem cell transplantation. Laboratory studies have demonstrated that iron is essential for Aspergillus growth and virulence.

METHODS. In the current study, the authors retrospectively evaluated the bone marrow iron stores (BMIS) in patients with leukemia as well as recipients of allogeneic hematopoietic stem cell transplantation with IA (n = 33) and those without fungal infections (n = 33). The first available bone marrow biopsy specimens prior to the IA diagnosis or date of hospitalization (control group) were assessed in a blinded fashion using a standardized scoring system (0–4). Both groups were comparable with regard to clinical characteristics and classic risk factors for IA.

RESULTS. The majority of patients with IA (70%) were found to have increased BMIS (score ≥3) compared with the control patients (16%) (P < .0001). Increased BMIS was found to be an independent risk factor for IA on multivariate analysis (P < .0001).

CONCLUSIONS. The prospective validation of BMIS for risk stratification in patients with leukemia or those who undergo allogeneic hematopoietic stem cell transplantation is needed.

KEYWORDS: aspergillosis, iron, bone marrow, leukemia, risk factors.
Recent laboratory studies demonstrated that iron acquisition is essential for the increased growth and virulence of *Aspergillus*. In addition, small case series implied that IA is associated with iron overload in patients with hematologic malignancies. Because patients with leukemia or myelodysplastic syndrome (MDS) and recipients of allogeneic HSCT receive frequent blood transfusions, the possibility of iron overload as a risk factor for IA should be evaluated further. Thus, in the current study, we sought to determine whether iron overload as measured using bone marrow iron stores (BMIS) is an independent risk factor for IA in patients with leukemia or allogeneic HSCT recipients.

**MATERIALS AND METHODS**

The medical records of 33 hospitalized patients with hematologic malignancies who had IA (study group) and 33 high-risk hospitalized patients without any fungal infections (contemporaneous control group) who were selected from a cohort of patients in a published case-control study from our institution (between September 2002 and March 2004) and for whom bone marrow biopsy slides were available were reviewed retrospectively. IA was defined according to published guidelines. Both groups were matched with regard to date of hospitalization. The groups were compared in terms of demographics and clinical characteristics (type and status of malignancy, receipt of HSCT, neutropenia, GVHD, receipt of a significant cumulative corticosteroid dose, comorbidities, and CMV infection). The first available bone marrow biopsy specimens with regard to IA diagnosis (study group) or the day of hospitalization (control group) were assessed in a blinded fashion by an experienced hematopathologist (X. H.).

Pearl blue iron stains were performed with bone marrow aspirate smears from archived pathologic materials. BMIS were calculated using a standardized scoring system (0–4). Briefly, scores of 0, 1+, and 2+ indicate absent, minimal, and moderate amounts of stainable iron within the bone marrow particles, respectively, whereas scores of 3+ and 4+ indicate the presence of moderately and markedly increased stainable iron stores, respectively. Increased BMIS were defined by a score of ≥3. Severe neutropenia was defined as ≤100 polymorphonuclear cells/mm³ for >10 days. Significant corticosteroid use was defined as the use of >600 mg of prednisone equivalent within 1 month from the diagnosis of IA.

The Fisher exact test and Mann-Whitney *U* test were used for comparisons of categoric and continuous variables, respectively. Patient risk factors that were independently associated with the development of IA were determined using forward stepwise regression analysis. All variables with a *P* value ≤ 0.2 on univariate analysis were screened for inclusion in the model. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were reported for all statistically significant variables at *P* ≤ .05. All analyses were performed using the Stata Rel 8.0 software program (StataCorp, College Station, TX).

**RESULTS**

All but 1 of the patients in the study group had pulmonary IA; nearly half (16 patients; 48%) had IA because of *Aspergillus fumigatus*, and 27 patients (82%) had breakthrough IA after the prior use of antifungals. The 12-week mortality rate in the study group was 70% (19 of 27 patients). The median day of BMIS evaluation with respect to IA diagnosis was comparable in both groups (Table 1) (*P* = .3). Both groups were comparable with regard to demographics and clinical characteristics including age, sex, malignancy type and status, receipt of HSCT, neutropenia, GVHD, receipt of a significant cumulative corticosteroid dose, and CMV infection. However, the median Acute Physiological and Chronic Health Evaluation (APACHE) II score was found to be higher in the study group (13; range, 5–22) compared with the control group (12; range, 5–22) (*P* = .04). The majority of the patients with IA (23 of 33 patients [70%]) had increased BMIS scores (≥3) compared with the control patients (6 of 33 patients [18%]) (*P* < .0001) (Fig. 1). On multivariate analysis, an increased BMIS score (OR of 12.3; 95% CI, 3.4–44.9 [*P* < .0001]) and an APACHE II score > 11 (OR of 5.16; 95% CI, 1.3–20.5 [*P* = .01]) were found to be independently associated with an increased risk of IA. Because the higher median APACHE II score in the IA group compared with the control group could likely reflect differences in the net state of immunosuppression in these patients rather than being a risk factor for IA per se, we repeated multivariate analysis after excluding the APACHE score and found that increased BMIS was the only significant variable associated with IA (OR of 12.4; 95% CI, 3.9–38.9 [*P* < .0001]).

**DISCUSSION**

Because the immunopathogenesis of IA remains largely unexplored, much remains to be learned regarding novel risk factors and better risk stratification in the complex patient population with hematologic malignancies. Previous studies found iron overload in 15% to 20% of patients with leukemia
and recipients of HSCT. Several factors may have accounted for these increased iron stores, including ineffective erythropoiesis, the frequent administration of blood products, and expression of inactive variants of iron-binding proteins. Several in vitro and clinical studies have linked iron overload with an increased risk of bacterial and invasive fungal infections, especially Zygomycetes infections. Fungi scavenge iron and overcome iron withholding by the host in several ways, such as the use of iron-binding proteins (siderophores). Therefore, a net increase in host iron stores would increase iron availability and enhance fungal growth.

To our knowledge, of the few studies associating IA with iron overload, the majority were limited by small patient numbers, heterogeneity, and a lack of a control group to account for the contribution of “classical” IA risk factors. Furthermore, some studies and clinical studies have linked iron overload with gal infections, especially Zygomycetes infections.

**TABLE 1**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control patients</th>
<th>Patients with IA</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median day of BMIS evaluation (range)</td>
<td>–9 (–160 to –180)</td>
<td>–9 (–344 to –85)</td>
<td>–</td>
<td>.3000</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Median age (range), y</td>
<td>50 (2–78)</td>
<td>56 (25–78)</td>
<td>–</td>
<td>.3500</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Male sex</td>
<td>18/33 (55%)</td>
<td>20/33 (61%)</td>
<td>–</td>
<td>.8000</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MDS or AML</td>
<td>11/33 (33%)</td>
<td>15/33 (45%)</td>
<td>–</td>
<td>.4500</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Active malignancy</td>
<td>17/33 (52%)</td>
<td>24/33 (73%)</td>
<td>–</td>
<td>.1700</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Neutropenia (&lt; 500 cells/mm3) at diagnosis</td>
<td>12/33 (36%)</td>
<td>14/33 (42%)</td>
<td>–</td>
<td>.6200</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Severe neutropenia (&lt; 100 cells/mm3 for &gt; 10 days)</td>
<td>6/33 (18%)</td>
<td>7/33 (21%)</td>
<td>–</td>
<td>.7500</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Lymphopenia (&lt; 500 cells/mm3)</td>
<td>17/33 (52%)</td>
<td>21/33 (64%)</td>
<td>–</td>
<td>.4500</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Active malignancy</td>
<td>12/33 (36%)</td>
<td>14/33 (42%)</td>
<td>–</td>
<td>.8000</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Significant corticosteroid use</td>
<td>8/33 (24%)</td>
<td>14/33 (42%)</td>
<td>–</td>
<td>.1900</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Allogeneic HCT</td>
<td>8/33 (24%)</td>
<td>14/33 (42%)</td>
<td>–</td>
<td>.1900</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>GVHD</td>
<td>2/8 (25%)</td>
<td>8/14 (57%)</td>
<td>–</td>
<td>.2000</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CMV reactivation</td>
<td>3/33 (9%)</td>
<td>9/33 (27%)</td>
<td>–</td>
<td>.1800</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>History of diabetes mellitus</td>
<td>4/33 (12%)</td>
<td>7/33 (21%)</td>
<td>–</td>
<td>.5100</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>APACHE II score &gt; 11</td>
<td>17/33 (52%)</td>
<td>26/33 (79%)</td>
<td>3.5 (1.2–10.3)</td>
<td>.0300</td>
<td>5.16 (1.3–20.5)</td>
<td>.0100</td>
</tr>
<tr>
<td>Increased BMIS score (≥3)</td>
<td>6/33 (18%)</td>
<td>23/33 (70%)</td>
<td>10.4 (3.2–32.8)</td>
<td>&lt; .0001</td>
<td>12.3 (3.4–44.9)</td>
<td>&lt; .0001</td>
</tr>
</tbody>
</table>

IA indicates invasive aspergillosis; OR, odds ratio; 95% CI, 95% confidence interval; BMIS, bone marrow iron stores; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia; HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; CMV, cytomegalovirus; APACHE, Acute Physiological and Chronic Health Evaluation.

* The days of BMIS evaluation were assessed with respect to the day of diagnosis of IA (study group) or the day of hospitalization (control group). There were no statistically significant differences noted with regard to the date of hospitalization between the patients in the study and those in the control group (data not shown).

1 Of the 33 patients with hematologic malignancies and IA, 10 had AML, 9 had non-Hodgkin lymphoma, 5 had MDS, 2 had acute lymphoblastic leukemia, 2 had chronic lymphocytic leukemia, 2 had chronic myelogenous leukemia, 2 had Hodgkin disease, and 1 had multiple myeloma. Of the 33 control patients with hematologic malignancies, 10 had non-Hodgkin lymphoma, 9 had AML, 4 had acute lymphoblastic leukemia, 4 had chronic lymphocytic leukemia, 2 had MDS, 2 had multiple myeloma, and 2 had chronic myelogenous leukemia.

1 At the time of diagnosis.

5 Prednisone equivalent (> 600 mg) administered during the month before the diagnosis of IA was made.

6 Four of 8 allogeneic HCT recipients in the control group (50%) and 7 of 14 allogeneic HCT recipients in the study group (50%) received transplants from mismatched related or matched unrelated donors (P = .80).

7 Increased BMIS (≥3) was found to be the only independent factor associated with IA (P < .0001; OR of 12.4 [95% CI, 3.9–38.9]) on stepwise logistic regression analysis performed after excluding the APACHE II score from the model.

8 A total of 23, 8, 5, and 1 control patients and 5, 5, 16, and 18 patients with IA had an iron score on bone marrow biopsy analysis with a BMIS score of +1, +2, +3, and +4, respectively.
used surrogate markers for iron overload that are either cumbersome, such as the calculation of liver iron stores or, as in the case of serum ferritin levels, unreliable because of the effects of inflammation and liver injury commonly observed in high-risk hematology patients.\textsuperscript{5,7} However, Strasser et al. demonstrated a strong correlation between bone marrow iron staining and biochemical bone marrow and liver iron stores.\textsuperscript{17} Although interobserver variability may exist in the assessment of BMIS, the semiquantitative grading system used by most hematopathologists to assess these stores is highly reproducible and validated for the diagnosis of moderate/severe iron overload.\textsuperscript{18}

To our knowledge, Miceli et al. were the first to describe an association between pretransplantation increased BMIS and severe infections in 367 autologous HSCT recipients with multiple myeloma.\textsuperscript{15} They found no association between increased BMIS and fungal infections, including IA, possibly because of the low prevalence of IA in the patient population studied.

Compared with previous studies regarding the association between iron overload and IA, the current study had the advantage of including a contemporaneous control group to avoid selection bias and adjust for confounding variables. Nonetheless, limitations of our study include its retrospective nature and the absence of data regarding the date of diagnosis of the underlying malignancy, the type and number of chemotherapeutic regimens, prior blood cell transfusions, other surrogate markers of iron overload such as ferritin, and free iron blood levels. Importantly, we cannot rule out the possibility that other differences among the groups could have influenced the validity of the current study findings. Therefore, a causal relation between increased BMIS and the occurrence of IA cannot be inferred from our study.

Prospective studies are needed to further elucidate the role of iron overload in the pathogenesis of IA in patients with hematologic malignancies and recipients of HSCT. Evaluating the role of promising new iron chelators such as deferasirox\textsuperscript{19} as prophylactic agents in high-risk patients with increased BMIS or as adjunctive therapy with antifungals in patients with established IA could be an interesting research direction.

REFERENCES

4. Hissen AH, Wan AN, Warwas ML, Pinto LJ, Moore MM. The \textit{Aspergillus fumigatus} siderophore biosynthetic gene 